Negative remnant 99mTc-pertechnetate uptake predicts excellent response to radioactive iodine therapy in low- to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy

2018 ◽  
Vol 33 (2) ◽  
pp. 112-118 ◽  
Author(s):  
Wei Lan ◽  
Zhao Gege ◽  
Lv Ningning ◽  
Wen Qiang ◽  
Bai Lin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Intermediate Risk ◽  
Radioactive Iodine Therapy ◽  
Excellent Response ◽  
99Mtc Pertechnetate

Effects of Total Thyroidectomy and Radioactive Iodine Therapy for Thyroid Cancer Patients on Sleep Apnea and Snoring

2015 ◽  
Vol 54 (4) ◽  
pp. 495
Author(s):  
Seung-Hyun Oh ◽  
Cheol-Seung Kim ◽  
Mal-Rye Choi ◽  
Eun-Hae Choi ◽  
Hyeong-Wook Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Sleep Apnea ◽  
Total Thyroidectomy ◽  
Cancer Patients ◽  
Radioactive Iodine ◽  
Radioactive Iodine Therapy

Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer— is there a need for radioactive iodine therapy?

Surgery ◽  
2012 ◽  
Vol 152 (6) ◽  
pp. 1096-1105 ◽  
Author(s):  
Tihana Ibrahimpasic ◽  
Iain J. Nixon ◽  
Frank L. Palmer ◽  
Monica M. Whitcher ◽  
Robert M. Tuttle ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Papillary Thyroid Cancer ◽  
Radioactive Iodine ◽  
Intermediate Risk ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

scholarly journals Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients

2013 ◽  
Vol 169 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Maria Grazia Castagna ◽  
Gabriele Cevenini ◽  
Alexandra Theodoropoulou ◽  
Fabio Maino ◽  
Silvia Memmo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Recurrent Disease ◽  
Intermediate Risk ◽  
Persistent Disease ◽  
Thyroid Ablation ◽  
The Impact

BackgroundIn differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no evidences are provided regarding the optimal radioactive iodine (RAI) activity to be administered for post-surgical thyroid ablation.MethodsThis study aimed to evaluate the impact of RAI activities on the outcome of 225 DTC patients classified as intermediate risk, treated with low (1110–1850 MBq) or high RAI activities (≥3700 MBq).ResultsSix to 18 months after ablation, remission was observed in 60.0% of patients treated with low and in 60.0% of those treated with high RAI activities, biochemical disease was found in 18.8% of patients treated with low and in 14.3% of patients treated with high RAI activities, metastatic disease was found in 21.2% of patients treated with low and in 25.7% of patients treated with high RAI activities (P=0.56). At the last follow-up (low activities, median 4.2 years; high activities, median 6.9 years), remission was observed in 76.5% of patients treated with low and in 72.1% of patients treated with high RAI activities, persistent disease was observed in 18.8% of patients treated with low and in 23.5% of patients treated with high RAI activities, recurrent disease was 2.4% in patients treated with low and 2.1% in patients treated with high RAI activities, deaths occurred in 2.4% of patients treated with low and in 2.1% of patients treated with high RAI activities (P=0.87).ConclusionOur study provides the first evidence that in DTC patients at intermediate risk, high RAI activities at ablation have no major advantage over low activities.

Sign in / Sign up

Export Citation Format

Share Document